We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Veracyte (VCYT - Free Report) ten years ago? It may not have been easy to hold on to VCYT for all that time, but if you did, how much would your investment be worth today?
Veracyte's Business In-Depth
With that in mind, let's take a look at Veracyte's main business drivers.
Headquartered in San Francisco, CA, Veracyte is a global diagnostics company that provides clinicians valuable insights to diagnose and treat cancer. The company has a wide array of advanced genomic tests that leverage deep scientific, clinical and machine learning expertise and other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), Envisia (interstitial lung diseases) and Decipher Bladder (bladder cancer), with additional tests in development.
These high-performing tests improve diagnostic, prognostic and treatment decisions in cancer and other challenging diseases, helping patients avoid unnecessary procedures and reduce time in finding appropriate treatment. In the United States, Veracyte offers tests through its central laboratories and makes the tests accessible to patients worldwide by collaborating with local labs.
The company recognizes revenues from three sources:
Testing revenues (94% of total revenues in 2024, up 28% from 2023): Upon delivery of the test results, the company bills for testing services considering factors such as payer reimbursement history, contracts and coverage.
Product revenues (3% of 2024 revenues; down 12%): Includes revenues from Prosigna breast cancer assay, the nCounter Analysis System (acquired from Nanostring Technologies, Inc. in 2019) and related diagnostic kits.
Biopharmaceutical and other revenues (3% of 2024 revenues; down 30%): Includes revenues from licensing or providing access to the company’s assets and services, including testing and contract manufacturing.
The company’s 2021 acquisition of Decipher Biosciences expanded its genomic testing menu into urologic cancers and provided Decipher GRID (Genomic Resource for Intelligent Discovery) — a platform and database that helps drive biopharmaceutical partnerships, key opinion leaders (KOL) engagement and pipeline development in urologic cancers.
In the same year, Veracyte acquired HalioDx, which enabled it to produce its own in vitro diagnostic (IVD) test kits for use on the nCounter Analysis System. Veracyte intends to migrate the manufacture of the test kits for the nCounter from NanoString to HalioDx.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Veracyte, ten years ago, you're likely feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in August 2015 would be worth $3,426.77, or a gain of 242.68%, as of August 29, 2025, and this return excludes dividends but includes price increases.
In comparison, the S&P 500's gained 226.91% and the price of gold went up 189.82% over the same time frame.
Going forward, analysts are expecting more upside for VCYT.
Veracyte continues the strong growth momentum in its testing business from the sale of Decipher Prostate and Afirma tests. Afirma's volume growth reflects both new accounts and deeper penetration of existing accounts, signaling continued market share gains. The research use-only Afirma GRID offering is also gaining traction. As a key milestone, Veracyte is on track to exceed 100,000 Decipher tests annually for the first time, driven by robust 2025 second-quarter volumes. Progress in terms of all three of its long-term growth drivers is also encouraging. Solid financial health further enhances the stock's appeal. Meanwhile, the sale of Veracyte SAS manufacturing business creates a temporary revenue headwind. The adverse impacts of macroeconomic challenges and an intense competitive landscape may pose operational risks.
The stock has jumped 27.39% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 3 higher, for fiscal 2025; the consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Veracyte (VCYT - Free Report) ten years ago? It may not have been easy to hold on to VCYT for all that time, but if you did, how much would your investment be worth today?
Veracyte's Business In-Depth
With that in mind, let's take a look at Veracyte's main business drivers.
Headquartered in San Francisco, CA, Veracyte is a global diagnostics company that provides clinicians valuable insights to diagnose and treat cancer. The company has a wide array of advanced genomic tests that leverage deep scientific, clinical and machine learning expertise and other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), Envisia (interstitial lung diseases) and Decipher Bladder (bladder cancer), with additional tests in development.
These high-performing tests improve diagnostic, prognostic and treatment decisions in cancer and other challenging diseases, helping patients avoid unnecessary procedures and reduce time in finding appropriate treatment. In the United States, Veracyte offers tests through its central laboratories and makes the tests accessible to patients worldwide by collaborating with local labs.
The company recognizes revenues from three sources:
Testing revenues (94% of total revenues in 2024, up 28% from 2023): Upon delivery of the test results, the company bills for testing services considering factors such as payer reimbursement history, contracts and coverage.
Product revenues (3% of 2024 revenues; down 12%): Includes revenues from Prosigna breast cancer assay, the nCounter Analysis System (acquired from Nanostring Technologies, Inc. in 2019) and related diagnostic kits.
Biopharmaceutical and other revenues (3% of 2024 revenues; down 30%): Includes revenues from licensing or providing access to the company’s assets and services, including testing and contract manufacturing.
The company’s 2021 acquisition of Decipher Biosciences expanded its genomic testing menu into urologic cancers and provided Decipher GRID (Genomic Resource for Intelligent Discovery) — a platform and database that helps drive biopharmaceutical partnerships, key opinion leaders (KOL) engagement and pipeline development in urologic cancers.
In the same year, Veracyte acquired HalioDx, which enabled it to produce its own in vitro diagnostic (IVD) test kits for use on the nCounter Analysis System. Veracyte intends to migrate the manufacture of the test kits for the nCounter from NanoString to HalioDx.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Veracyte, ten years ago, you're likely feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in August 2015 would be worth $3,426.77, or a gain of 242.68%, as of August 29, 2025, and this return excludes dividends but includes price increases.
In comparison, the S&P 500's gained 226.91% and the price of gold went up 189.82% over the same time frame.
Going forward, analysts are expecting more upside for VCYT.
Veracyte continues the strong growth momentum in its testing business from the sale of Decipher Prostate and Afirma tests. Afirma's volume growth reflects both new accounts and deeper penetration of existing accounts, signaling continued market share gains. The research use-only Afirma GRID offering is also gaining traction. As a key milestone, Veracyte is on track to exceed 100,000 Decipher tests annually for the first time, driven by robust 2025 second-quarter volumes. Progress in terms of all three of its long-term growth drivers is also encouraging. Solid financial health further enhances the stock's appeal. Meanwhile, the sale of Veracyte SAS manufacturing business creates a temporary revenue headwind. The adverse impacts of macroeconomic challenges and an intense competitive landscape may pose operational risks.
The stock has jumped 27.39% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 3 higher, for fiscal 2025; the consensus estimate has moved up as well.